COO

Business Context and Reporting Period

Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and six months ended April 30, 2002
Business Overview: Cooper operates two primary segments: CooperVision (CVI), which markets specialty contact lenses, and CooperSurgical (CSI), which markets diagnostic products and surgical instruments for gynecologists and obstetricians.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 26% ($14.7 million) for the quarter and 21% ($22.8 million) for the six-month period compared to the prior year. Growth was driven by both organic volume increases and acquisitions.
• Acquisition Impact: The acquisition of Biocompatibles International plc (Feb 2002) and Norland Medical Systems (Apr 2002) significantly contributed to revenue and operating income. Excluding these acquisitions, organic soft lens revenue growth was 4% for the quarter and 10% year-to-date.
• Margin Compression: Gross margin decreased 5 percentage points to 61% for the quarter and 3 percentage points to 63% for the six-month period. This decline is attributed to a higher mix of sales through distributors (lower margin) and the integration of acquired businesses.
• Amortization Reduction: Amortization of intangibles dropped significantly (67% for the quarter) due to the adoption of SFAS 142, which eliminated goodwill amortization.
• Debt Increase: Total debt rose from $68.8 million to $164.6 million, primarily due to borrowings used to fund the Biocompatibles acquisition.

Outlook, Risks, and Management Commentary

• Guidance & Tax Rate: Management estimates the effective tax rate for fiscal 2002 will be 27%, down from 32% in the prior year, due to a higher percentage of income from international operations. The rate is expected to decline further to approximately 26% in fiscal 2003.
• Liquidity & Financing: On May 1, 2002 (subsequent to period end), Cooper secured a new $225 million bank credit facility to repay acquisition-related notes and fund future operations. The company expects cash flow from operations to fund dividends and smaller acquisitions.
• Operational Improvements: Days Sales Outstanding (DSO) improved to 73 days (excluding new acquisitions) from 86 days in the prior quarter, following the resolution of issues with a new enterprise reporting system. The target is 70-72 days by year-end.
• Legal Contingencies: Wesley Jessen Corporation (WJ) has filed lawsuits in the U.S., UK, and France alleging patent infringement regarding CooperVision's "Frequency Colors" opaque contact lenses. Revenue from these products was approximately $2.1 million for the six months ended April 30, 2002. Cooper intends to vigorously defend these actions.
• Subsequent Acquisitions: On May 21, 2002, Cooper acquired Ackrad Laboratories for $12 million, expected to be accretive to earnings within 12 months.

Investor Verification Checklist

• Acquisition Integration: Verify the timeline and cost savings associated with integrating Biocompatibles and Norland to confirm margin recovery projections.
• Patent Litigation: Monitor the status of the Wesley Jessen Corporation lawsuits in the U.S., UK, and France, as an adverse ruling could impact the "Frequency Colors" product line revenue.
• Debt Covenants: Review the new $225 million credit facility terms, specifically the 50% debt-to-capitalization limit and the 1.3:1 EBITDA-to-fixed-charges ratio requirement.
• DSO Trends: Track Days Sales Outstanding to ensure it returns to the 70-72 day target, as collection issues previously impacted working capital.
• Goodwill Valuation: Note that goodwill is no longer amortized under SFAS 142; monitor future impairment testing results for the $200 million goodwill balance.